Prima BioMed (PRR) - Preliminary LAG-3 combo data in breast cancer

06:48 EDT 23 Jun 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Prima BioMed: Preliminary efficacy data, which Prima BioMed presented at ASCO from the 15-patient, safety run-in phase of its AIPAC study, showed sustained immune activation and an encouraging 47% tumour response rate in breast cancer following IMP321 plus paclitaxel combination therapy. Recruitment in the randomised Phase IIb component of AIPAC is ongoing, with top-line data likely by mid-2019. Efficacy data from the final two cohorts in the TACTI-mel trial of IMP321 plus Keytruda in melanoma are expected in H217 and H118 respectively. The 47% AIPAC response rate is in line with Phase I studies and consistent with our expectations, so we leave our valuation unchanged at A$252m (12c per share).
ISIN: AU000000PRR9

Original Article: Prima BioMed (PRR) - Preliminary LAG-3 combo data in breast cancer


More From BioPortfolio on "Prima BioMed (PRR) - Preliminary LAG-3 combo data in breast cancer"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...